Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4.

Journal:

Journal of Clinical Oncology

Published:

2025-12-04

DOI:

10.1200/jco-25-02382

Affiliations:

21

Authors:

22

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	6.000000	0.27
University of Florida (UF), United States of America (USA)	1.000000	0.05
Fred Hutchinson Cancer Center, United States of America (USA)	1.000000	0.05
Bichat-Claude Bernard Hospital, France	1.000000	0.05
Johnson & Johnson, Spain, Spain	1.000000	0.05
Hospital Universitario 12 de Octubre, Spain	1.000000	0.05
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.05
Institute of Biomedical Research in Malaga (IBIMA), Spain	1.000000	0.05
Miami Cancer Institute, United States of America (USA)	1.000000	0.05
University Hospital of Münster (UKM), WWU, Germany	1.000000	0.05
Clinique La Croix du Sud, France	1.000000	0.05
Johnson & Johnson Consumer France SAS, France	1.000000	0.05
Seoul National University Hospital (SNUH), South Korea	1.000000	0.05
START Carolinas, United States of America (USA)	1.000000	0.05
Queen Mary University of London (QMUL), United Kingdom (UK)	0.500000	0.02
IRCCS San Raffaele Hospital (HSR), Italy	0.500000	0.02
University College London Hospitals NHS Foundation Trust (UCLH), United Kingdom (UK)	0.500000	0.02
Brigham and Women's Hospital (BWH), United States of America (USA)	0.500000	0.02
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	0.500000	0.02
Vita-Salute San Raffaele University (UniSR), Italy	0.500000	0.02

Interested in Oncology and Carcinogenesis?